West London Mental Health NHS Trust Formulary
|
|
- Jason Higgins
- 5 years ago
- Views:
Transcription
1 West London Mental Health NHS Trust Formulary VERSION 3.0 ( ) The Formulary is a list of medicines used for mental health indications for patients cared for in all settings of West London Mental Health NHS Trust. The Formulary is intended to cover prescribing in Mental Health Conditions and the Management of adverse effects related to the medication for: prescriptions written for inpatients; prescriptions or recommendations by Trust doctors in respect of outpatients or patients leaving hospital after an admission. The evidence base for the formulary has been based on the Maudsley Prescribing Guidelines. The Formulary should be taken fully into account by prescribers when exercising their clinical judgement. However, it does not override the individual responsibility of prescribers to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer and informed by the summary of product characteristics of any medicines they are considering. Prescribing outside of the formulary will require a discussion with the Team pharmacist before the medication can be ordered by pharmacy and clinicians should be aware that items will not be kept in pharmacy and there may be a delay in supply. People currently receiving a medicine that is not included in the Formulary should have the option to continue until they and their clinicians consider it appropriate to stop. Mental Health medicines recommended by NICE technology appraisal guidance (TAG) will, where clinically appropriate, be included in the Formulary within 90 days of the date the TAG is published. initiation A number of medicines in the Formulary are marked specialist initiation by NWL. The medicine should initially be prescribed by a mental health specialist with monitoring of effectiveness and toxicity, until treatment is stable at which point the patient s GP can be asked whether s/he will take over prescribing, however it is reasonable for a GP to write the first prescription after a telephone conversation with a mental health specialist clinician if the medication is included in the NWL integrated formulary. Different GPs might reasonably take different decisions regarding whether or when to prescribe, depending on their knowledge and experience. Legal responsibility for prescribing lies with the doctor who signs the prescription. Hospital Only Medicines (Red List) Medicines marked as Hospital Only should only be prescribed by Trust Clinicians and should not be referred to primary care for prescribing Medicines Not included in the NWL Integrated Formulary The NWL IF has been developed to co-ordinate prescribing across the primary/secondary care setting throughout NWL. However it is recognised that medicines may be initiated in hospital which are not covered by the NWL IF. In these cases the Trust doctor must provide clear rationale to the GP for prescribing, including why medicines on the IF are not appropriate. Physical Health Prescribing Prescribing for physical health medications should be in line with the North West London integrated formulary (NWL IF), and, where possible be a medication stocked by the Trust pharmacy department. Minor Ailment Medication Although these have not been included in the mental health formulary, a list of medicines from the NWL IF stocked in pharmacy for nausea and vomitting, infections and analgesia have been included as a seperate list to assist prescribers decision making in these areas. BNF chapter BNF section BNF sub-section 2. Cardiovascular system 2. Cardiovascular system 2. Cardiovascular system 3. Respiratory system 2.4 Beta-adrenoceptor blocking drugs 2.4 Bisoprolol 2.4 Beta-adrenoceptor blocking drugs 2.4 Propranolol 2.12 Lipid-regulating drugs Other 3.4 Antihistamines, hyposensitisation, and allergic emergencies Omacor (omega-3 acid ethyl esters) Promethazine MR capsules capsules (Omacor and Maxepa). elixir injection For use in clozapine induced Tachycardia For use as an anxiolytic or for the management of akathesia Treatment resistant psychosis (off-label not on Trust approved list) Maxepa is considerably cheaper Licensed Indication Insomnia Injection reserved for RT (off-label) (, elixir) 1 of 13
2 BNF chapter BNF section BNF sub-section 4.1 Hypnotics and anxiolytics Hypnotics Zopiclone 4.1 Hypnotics and anxiolytics Hypnotics Zolpidem tartrate 4.1 Hypnotics and anxiolytics Hypnotics Temazepam 4.1 Hypnotics and anxiolytics Lorazepam 4.1 Hypnotics and anxiolytics Diazepam injection rectal tubes Diazemul injection When a short acting hypnotic is indicated NICE recommend the cheapest of short-acting benzodiazepine, zaleplon, zolpidem or zopiclone. Zolpidem and zopiclone are currently the lowest cost drugs. When a short acting hypnotic is indicated NICE recommend the cheapest of short-acting benzodiazepine, zaleplon, zolpidem or zopiclone. Zolpidem and zopiclone are currently the lowest cost drugs. When a short acting hypnotic is indicated NICE recommend the cheapest of short-acting benzodiazepine, zaleplon, zolpidem or zopiclone. Zolpidem and zopiclone are currently the lowest cost drugs. () Diazemul Injection reserved for RT (Tablets,, rectal tubes) 4.1 Hypnotics and anxiolytics Chlordiazepoxide capsules 4.1 Hypnotics and anxiolytics Buspirone Antipsychotic drugs Trifluoperazine Antipsychotic drugs Sulpiride Antipsychotic drugs Quetiapine Antipsychotic drugs Olanzapine Antipsychotic drugs Chlorpromazine Antipsychotic drugs Aripiprazole Antipsychotic drugs Amisulpride Antipsychotic drugs Clozapine Antipsychotic drugs Risperidone Antipsychotic drugs Haloperidol Antipsychotic drugs Flupentixol Antipsychotic drugs Zuclopenthixol Aripiprazole Flupentixol decanoate tablet tablet MR orodispersible Orodispersible cost more than standard (Tablets, orodispersible) injection orodispersible liquid (unlicensed) orodispersible capsules oral liquid Injection Long Acting Injection depot injection Consultant (Hospital Only) NO - RED LIST Orodispersible cost much more than standard Injection reserved for RT (capsules,, oral liquid) First generation antipsychotic depots should be considered first line treatment option evidence of this is requiredaripiprazole LAI should only be used in patients who have responded to oral aripiprazole (4-6 weeks). If having to use more than one vial the same strength vials should be used to ensure the correct dose is received. It is recommended that the smallest volume is used for depot administration and in general should not exceed 2mls. 2 of 13
3 BNF chapter BNF section BNF sub-section Drugs used for mania and hypomania Drugs used for mania and hypomania Drugs used for mania and hypomania Drugs used for mania and hypomania Monoamine-oxidase inhibitors Monoamine-oxidase inhibitors Fluphenazine decanoate Haloperidol (as decanoate) Olanzapine Paliperidone Pipotiazine palmitate Risperidone Zuclopenthixol decanoate Valproic acid Lithium citrate Lithium carbonate Asenapine Clomipramine Trazodone Lofepramine Imipramine Amitriptyline Mianserin Nortriptyline Moclobemide Phenelzine depot injection depot injection Long Acting Injection Long Acting Injection depot injection Long Acting Injection depot injection E/C Tablets liquid (Priadel ) (Li-liquid ); (Camcolit,) MR (Priadel, Camcolit, Liskonum ) sublingual capsules capsules liquid oral suspension Consultant Only with Medical Director Approval If having to use more than one vial the same strength vials should be used to ensure the correct dose is received. It is recommended that the smallest volume is used for depot administration and in general should not exceed 2mls. If having to use more than one vial the same strength vials should be used to ensure the correct dose is received. It is recommended that the smallest volume is used for depot administration and in general should not exceed 2mls. Olanzapine LA has NOT been approved for General use however there is a process for assessing individual cases It is recommended that the smallest volume is used for depot administration and in general should not exceed 2mls. If having to use more than one vial the same strength vials should be used to ensure the correct dose is received. It is recommended that the smallest volume is used for depot administration and in general should not exceed 2mls. Prescribe by brand name Prescribe by brand name 3rd line use for mania Lower incidence of side effects and less dangerous in overdose than other tricyclic antidepressants, but infrequently associated with hepatic toxicity Consultant only 3 of 13
4 BNF chapter BNF section BNF sub-section Selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors Sertraline Fluoxetine Citalopram capsules liquid Selective serotonin reuptake inhibitors Paroxetine Paroxetine has a short half life and has been associated with more withdrawal effects than other SSRI's. 4.4 Central nervous system stimulants Other antidepressant drugs Other antidepressant drugs Other antidepressant drugs Venlafaxine Mirtazapine Agomelatine Methylphenidate MR Orodispersible (soluble) 5mg, 10mg; MR capsules 10mg, 20mg, 30mg (Equasym XL); MR capsules 10mg, 20mg, 30mg, 40mg (Medikinet XL); MR 18mg, 27mg, 36mg (Concerta XL ) Consultant Only In primary care Ordinary release cost less than MR which cost much less than MR capsules. Prescribe by Brand Shared care documents are in use in some parts of NWL. 4.4 Central nervous system stimulants 4.4 Atomoxetine Capsules Shared care documents are in use in some parts of NWL. 4.4 Central nervous system stimulants 4.4 Dexamfetamine sulphate 4.4 Central nervous system stimulants 4.4 Lisdexamfetamine CAMHS 4.4 Central nervous system stimulants 4.4 Modafinil Shared care documents are in use in some parts of NWL. For use when response to previous methylphenidate treatment is considered clinically inadequate. 4.8 Antiepileptics Topiramate 4.8 Antiepileptics Sodium valproate ec MR crushable liquid (sugar-free) Mood stabiliser and to reduce the risk of fitting for patients on clozapine > 600mg/d (off-label Trust approved) 4.8 Antiepileptics Pregabalin capsules For use in line with NICE's guidance 4.8 Antiepileptics Lamotrigine 4.8 Antiepileptics Clonazepam 25mg, 50mg, 100mg, 200mg; dispersible 5mg, 25mg, 100mg tablet 500micrograms, 2mg; injection Anxiety and Agitation (off-label Trust approved) 4.8 Antiepileptics Carbamazepine 100mg, 200mg, 400mg; MR 200mg, 400mg; chewable 100mg, 200mg; liquid 100mg in 5ml 4 of 13
5 BNF chapter BNF section BNF sub-section 4.9 Drugs used in parkinsonism and 4.9 Drugs used in parkinsonism and 4.9 Drugs used in parkinsonism and 4.10 Drugs used in substance 4.10 Drugs used in substance 4.10 Drugs used in substance 4.10 Drugs used in substance 4.10 Drugs used in substance 4.10 Drugs used in substance 4.10 Drugs used in substance 4.10 Drugs used in substance 4.10 Drugs used in substance 4.10 Drugs used in substance Trihexyphenidyl Procyclidine Orphenadrine Alcohol Disulfiram Alcohol Acamprosate Calcium Alcohol Nalmefene Nicotine Nicotine Nicotine Buproprion Nicotine Varenicline Opioid Methadone Opioid Buprenorphine + naloxone Opioid Buprenorphine Opioid Naltrexone 4.11 Drugs used for dementia 4.11 Rivastigmine 4.11 Drugs used for dementia 4.11 Memantine 4.11 Drugs used for dementia 4.11 Galantamine 4.11 Drugs used for dementia 4.11 Donepezil syrup sugar free syrup tablet tablet tablet tablet patches (all strengths); chewing gum 2mg, 4mg; sublingual tablet 2mg; lozenge 1mg, 2mg, 4mg; inhalation 10mg; nasal spray Tablets, f/c, varenicline (as tartrate) 500 micrograms, 1 mg sugar-free 1mg in 1ml Suboxone 2mg/500micrograms; 8mg/2mg sublingual sublingual 400micrograms, 2mg, 8mg 50mg capsules 1.5mg, 3mg, 4.5mg, 6mg; 2mg/ml; patches 4.6mg/24 hours, 9.5mg/24 hours 10mg, 20mg; treatment initiation pack; 5mg/actuation 8mg, 12mg; MR capsules 8mg, 16mg, 24mg 4mg in 1ml 5mg, 10mg In line with NICE TA - See Trust Guidance initiated by, or on the written advice of, the Bipolar Affective Disorder Tertiary Referral Clinic Bipolar Affective Disorder (off-label Trust approved) Use in line with Trust Smoking Cessation Guideline. For outpatients refer to local smoking cessation services. Note MHRA/CHM advice on association with psychiatric symptoms including suicidal thoughts. Use in line with Trust Smoking Cessation Guideline. For outpatients refer to local smoking cessation services. Only for use in line with NICE's guidance. Shared care documents have been agreed in some parts of NWL and in these areas GPs should only be asked to prescribe the drug in line with the agreement. Only for use in line with NICE's guidance. Shared care documents have been agreed in some parts of NWL and in these areas GPs should only be asked to prescribe the drug in line with the agreement. Only for use in line with NICE's guidance. Shared care documents have been agreed in some parts of NWL and in these areas GPs should only be asked to prescribe the drug in line with the agreement. Only for use in line with NICE's guidance. Shared care documents have been agreed in some parts of NWL and in these areas GPs should only be asked to prescribe the drug in line with the agreement. 5 of 13
6 BNF chapter BNF section BNF sub-section Oestrogens and HRT Estradot 25 patch, 37.5 patch, 50 patch, 75 patch, 100 patch Oestrogen supplementation for recommendation by GIC (Off-label) Oestrogens and HRT Progynova Progynova 1mg ; Progynova 2mg Oestrogen supplementation for recommendation by GIC (Off-label) - provides more reliable levels than oestradiol hemihydrate Oestrogens and HRT Premarin 300micrograms, 625micrograms, 1.25mg Oestrogen supplementation for recommendation by GIC (Off-label) Oestrogens and HRT Sandrena Gel 0.1% 1mg/1g sachet Oestrogen supplementation for recommendation by GIC (Off-label) provides better and more reliable levels than oestrogel Oestrogens and HRT Ethinylestradiol Oestrogen supplementation for recommendation by GIC (Off-label) Injection Male sex hormones and antagonists Testosterone Undeconate Testosterone Supplementation for recommendation by GIC (Off-label) 5mg Male sex hormones and antagonists Finasteride Off-label use for recommendation by GIC Tablets Male sex hormones and antagonists Cyproterone acetate Licensed indication Control of libido in severe hypersexuality and/or sexual deviation in the adult male 6.5 Hypothalamic and pituitary hormones and anti-oestrogens Desmopressin Severe nocturnal enuresis due to clozapine when other measures have not been effective 6.7 Other endocrine drugs Bromocriptine Dopamine agonist - Maudsley recommended as a possible third line treatment for hyperprolactinaemia however may worsen psychosis and other preferable options are available 6.7 Other endocrine drugs Triptorelin 6.7 Other endocrine drugs Goserelin injection implant 10.8mg syringe N by GIC/Consultant only N by GIC/Consultant only Suppression of testosterone or to augment response to oestrogens for recommendation by GIC and treatment of hypersexuality (Off-label) Suppression of testosterone or to augment response to oestrogens for recommendation by GIC and treatment of hypersexuality (Off-label) 6 of 13
7 BNF chapter BNF section BNF sub-section 7. Obstetrics, gynaecology, and urinary-tract disorders 7.4 Drugs for genito-urinary disorders Drugs for erectile dysfunction Sildenafil See BNF for circumstances under which this can be prescribed on the NHS. Will be available generically sooner than similar drugs. 9. Nutrition and blood 9. Nutrition and blood 9. Nutrition and blood 9. Nutrition and blood 9.6 Vitamins Vitamin D 9.6 Vitamins Vitamin D Ergocalciferol (calciferol, vitamin D2) Colecalciferol (Cholecalciferol, vitamin D3) 9.6 Vitamins Vitamin D Calceos 9.6 Vitamins Vitamin D Adcal-D3 injection capsules 800 units, 3200 units (Fultium ), 20,000 units (Aviticol); Valupak 1,000 units (nutritional product) chewable, contain 12.5mmol calcium and 400 units colecalciferol (chewable), calcium carbonate 1.5g (calcium 600mg/15mmol), colecalciferol 10 micrograms (400 units) Availability of this UK licensed product is sporadic. Refer to local guidance on vitamin D. Also refer to local guidance on vitamin D products. 10. Musculoskeletal and joint diseases 10. Musculoskeletal and joint diseases 15. Anaesthesia 10.1 Drugs used in rheumatic disease and gout 10.2 Drugs used in neuromuscular disorders Gout and cytotoxicinduced hyperuricaemia Skeletal muscle relaxants Allopurinol Baclofen 15.1 General anaesthesia Benzodiazepines Midazolam 10mg; 5mg in 5ml injection 1mg/ml 5ml ampoules Consultant Initiation for TRS/MANIA Mausdley guidelines recommendation for TRS refractory to clozapine and in addition to lithium in mania TD For use when IM Lorazepam unavailable for RT For use in palliative care 15. Anaesthesia 15.1 General anaesthesia 15.1 General anaesthesia Antagonists for central and respiratory depression Antagonists for central and respiratory depression Naloxone Flumazenil injection 400micrograms in 1ml injection 100micrograms/ml 5ml ampoules Ensure that flumazenil is available where injectable benzodiazepines are used. 7 of 13
8 Mental Health NICE Technology Appraisals Technology Appraisal Medicines Guidance TA77 TA98 TA213 Zaleplon Zolpidem Zopicole Methylphenidate Atomoxetine Dexamfetamine Aripiprazole It is recommended that, because of the lack of compelling evidence to distinguish between zaleplon, zolpidem, zopiclone or the shorteracting benzodiazepine hypnotics, the drug with the lowest purchase cost (taking into account daily required dose and product price per dose) should be prescribed. It is recommended that switching from one of these hypnotics to another should only occur if a patient experiences adverse effects considered to be directly related to a specific agent. These are the only circumstances in which the drugs with the higher acquisition costs are recommended. Patients who have not responded to one of these hypnotic drugs should not be prescribed any of the others. Where drug treatment is considered appropriate, methylphenidate, atomoxetine and dexamfetamine are recommended, within their licensed indications, as options for the management of ADHD in children and adolescents. Aripiprazole is recommended as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone. TA217 Donepezil Galantamine Rivastigmine Memantine 1. The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine are recommended as options for managing mild to moderate Alzheimer s disease under all of the conditions specified in 3 and Memantine is recommended as an option for managing Alzheimer s disease for people with: moderate Alzheimer s disease who are intolerant of or have a contraindication to AChE inhibitors or severe Alzheimer s disease. Treatment should be under the conditions specified in Treatment should be under the following conditions: Only specialists in the care of patients with dementia (that is, psychiatrists including those specialising in learning disability, neurologists, and physicians specialising in the care of older people) should initiate treatment. Carers views on the patient s condition at baseline should be sought. Treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global, functional or behavioural symptoms. Patients who continue on treatment should be reviewed regularly using cognitive, global, functional and behavioural assessment. Treatment should be reviewed by an appropriate specialist team, unless there are locally agreed protocols for shared care. Carers views on the patient s condition at follow-up should be sought. 4. If prescribing an AChE inhibitor (donepezil, galantamine or rivastigmine), treatment should normally be started with the drug with the lowest acquisition cost (taking into account required daily dose and the price per dose once shared care has started). However, an alternative AChE inhibitor could be prescribed if it is considered appropriate when taking into account adverse event profile, expectations about adherence, medical comorbidity, possibility of drug interactions and dosing profiles.
9 Technology Appraisal Medicines Guidance TA292 Ariprazole Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder.aripiprazole is recommended as an option for treating moderate to severemanic episodes in adolescents with bipolar I disorder, within its marketingauthorisation (that is, up to 12 weeks of treatment for moderate to severemanic episodes in bipolar I disorder in adolescents aged 13 and older). Nalmefene is recommended within its marketing authorisation, as an option for reducing alcohol consumption, for people with alcohol : who have a high drinking risk level (defined as alcohol consumption of more than 60 g per day for men and more than 40 g per day for women, according to the World Health Organization's drinking risk levels) without physical withdrawal symptoms and who do not require immediate detoxification. The marketing authorisation states that nalmefene should: only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption and be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment. TA325 Nalmefene
10 BNF Category Stocked in Pharmacy NWL IF Notes 4.6 Drugs used in nausea and vertigo Domperidone 4.6 Drugs used in nausea and vertigo Cyclizine Non-opioid analgesics and compound analgesic preparations Paracetamol Non-opioid analgesics and compound analgesic preparations Co-dydramol Non-opioid analgesics and compound analgesic preparations Co-codamol Non-opioid analgesics and compound analgesic preparations Aspirin Non-opioid analgesics and compound analgesic preparations Nefopam Opioid analgesics Fentanyl Morphine Opioid analgesics sulphate Opioid analgesics Oxycodone Tramadol Opioid analgesics Metoclopramide is not recommended as this crosses the blood brain barrier and can cause EPSE Opioid analgesics Dihydrocodeine Opioid analgesics Codeine phosphate Opioid analgesics Buprenorphine Phenoxymethylpe 5.1 Antibacterial drugs nicillin (penicillin V)
11 BNF Category Stocked in Pharmacy NWL IF Notes 5.1 Antibacterial drugs Flucloxacillin 5.1 Antibacterial drugs Co-amoxiclav 5.1 Antibacterial drugs Amoxicillin Cefalexin 5.1 Antibacterial drugs (cephalexin) 5.1 Antibacterial drugs Oxytetracycline 5.1 Antibacterial drugs Lymecycline 5.1 Antibacterial drugs Doxycycline 5.1 Antibacterial drugs Demeclocycline 5.1 Antibacterial drugs Erythromycin 5.1 Antibacterial drugs Clarithromycin 5.1 Antibacterial drugs Azithromycin 5.1 Antibacterial drugs Clindamycin 5.1 Antibacterial drugs Trimethoprim 5.1 Antibacterial drugs Metronidazole 5.1 Antibacterial drugs Ciprofloxacin 5.1 Antibacterial drugs Moxifloxacin 5.1 Antibacterial drugs Ofloxacin 5.1 Antibacterial drugs Nitrofurantoin 5.2 Antifungal drugs Terbinafine 5.2 Antifungal drugs Nystatin 5.2 Antifungal drugs Itraconazole 5.2 Antifungal drugs Fluconazole 5.3 Antiviral drugs Aciclovir
12 BNF Category Stocked in Pharmacy NWL IF Notes 5.3 Antiviral drugs Oseltamivir Non-steroidal anti-inflammatory drugs Ibuprofen Non-steroidal anti-inflammatory drugs Naproxen Non-steroidal anti-inflammatory drugs Celecoxib initiation 11.3 Anti-infective eye preparations Chloramphenicol Eye Drops 11.3 Anti-infective eye preparations Fusidic acid Gel 11.8 Miscellaneous ophthalmic preparations (Dry Eye) Hypromellose 11.8 Miscellaneous ophthalmic preparations (Dry Eye) Carmellose 11.8 Miscellaneous ophthalmic preparations (Dry Eye) Carbomer 980 (viscotears) Otitis externa Sofradex Otitis externa Otomize Locorten-Vioform Otitis externa Otitis externa Gentisone HC Clotrimazole Removal of ear wax Sodium bicarbonate Removal of ear wax Olive oil
13 Version Date released Amendments Amended by /03/2013 Formulary 1st release Michele Sie Update following addition of two new medicines approved by /02/2014 DTC Michele Sie /02/2015 Update following publication of TA for Nalmefene Michele Sie
West London Mental Health NHS Trust Formulary
West London Mental Health NHS Trust Formulary VERSION 7.0 (09.11.16) The Formulary is a list of medicines used for mental health indications for patients cared for in all settings of West London Mental
More informationSouth London and the Maudsley NHS Foundation Trust Medicines Formulary
South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1
More informationMedicines Formulary BNF Section 4 Central Nervous System
Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam
More informationSafe transfer of prescribing guidance
Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed
More informationChapter 4 ~ Central nervous system
Chapter 4 ~ Central Nervous System: Special Section 1 of 5 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics LOPRAZOLAM Tablet 1mg LORMETAZEPAM Tablet 500microgram PROMETHAZINE
More informationNI Formulary: Chapter 4 Central Nervous system
Hypnotics Anxiolytics Acute state Non drug treatment Temazepam tablets 10mg, 20mg; oral solution 10mg/5ml or Zolpidem tablets 5mg, 10mg or Zopiclone 3.75mg, 7.5mg Non drug treatment Diazepam tablets 2mg,
More informationChapter 4 ~ Central nervous system
Chapter 4 ~ Central Nervous System: General Section 1 of 6 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics CHLORAL HYDRATE CLOMETHIAZOLE NITRAZEPAM TEMAZEPAM TRICLOFOS
More informationJoint Formulary for Psychotropic Medication.
Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Page 1 Table of Contents Section Page Number Page 2 Definition of categories
More informationThis document has been produced in collaboration with the Lancashire Commissioning Support Unit
Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Date: December 2014. Reviewed August 2016. Next review Date April 2019
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationNSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present.
Traffic Light Status NSFT Formulary Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Hospital/Specialist only Drugs for which the Trust
More informationFORMULARY AND PRESCRIBING GUIDELINES 2017
FORMULARY AND PRESCRIBING GUIDELINES 2017 1 Document Control Summary Issue Date Amended Section /page Author/ Amended by 1. Sept 06 All Jane Moriba Summary of Change Removed Trust policy and guideline
More informationFormulary Item Restrictions and/or Advice Site availability
Formulary Item Restrictions and/or Advice Site availability C&W CNWL Typical Antipsychotic drugs Chlorpromazine 25mg Chlorpromazine 50mg Chlorpromazine 100mg Chlorpromazine 25mg/5ml syrup Chlorpromazine
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationFORMULARY AND PRESCRIBING GUIDANCE
FORMULARY AND PRESCRIBING GUIDANCE GUIDELINE VERSION 18 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED NEXT REVIEW DATE (see specific guidelines) FORMULARY SPONSOR Executive Medical
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationPSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX
A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual
More informationDT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %
June 2016 On 13th May, the DH announced that there would be reductions to Category M prices from June until September. http://psnc.org.uk/our-news/contractor-notice-category-m-price-reduction/ This has
More informationFORMULARY AND PRESCRIBING GUIDANCE
FORMULARY AND PRESCRIBING GUIDANCE GUIDELINE VERSION 13 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED August 2014 NEXT REVIEW DATE (see specific guidelines) FORMULARY SPONSOR Executive
More informationFORMULARY AND PRESCRIBING GUIDELINES FOR CHILDREN AND ADOLESCENTS IN MENTAL HEALTH SERVICES
FORMULARY AND PRESCRIBING GUIDELINES FOR CHILDREN AND ADOLESCENTS IN MENTAL HEALTH SERVICES Version Control Summary Version Date Section(s) Author Comment(s)/Amendments 1 August 2008 All Sections Gbemi
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationAripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)
1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside
More informationT2/T3/S62/CT012 Aide Memoire
Correct way to fill out MHA forms T2/T3/S62/CTO12 SH CP 224 T2/T3/S62/CT012 Aide Memoire Version: 2 Summary: An Aide Memoire to completing or requesting a T2/T3/S62/CT012 Keywords: Target Audience: T2,
More informationCommunity Pharmacy Support Guidance: Electronic Repeat Dispensing (erd)
Community Pharmacy Support Guidance: Electronic Repeat Dispensing (erd) Version: 2.1 Date Published October 2018 Author: Rachel Raybould, Midland and Lancashire CSU 1 Introduction: Welcome to the Community
More informationDT Description Price Category Price change
Tariff T Watch October 2014 Readers are no doubt aware of this quarter's bad news for primary care prescribing allocations: NHS England has d the remuneration mechanism for community pharmacies gaining
More informationStop smoking products guidance
Stop smoking products guidance Ref: Status: Approved Stop smoking products guidance Page 1 of 15 Approval date: 22 November 2018 Contents 1. Purpose... 3 2. Related documents... 3 3. Guidance... 3 3.1
More informationUpper Peninsula Health Plan Advantage (HMO) (List of Covered Drugs)
Analgesics Opioid Analgesics, Long-acting fentanyl 100 mcg/hr patch td72 morphine sulfate 30 mg tablet er Opioid Analgesics, Short-acting fentanyl citrate 200 mcg lozenge hd hydrocodone/acetaminophen 5
More informationPreferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses
Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses HPFT Medicines Formulary lists the APDs that have been approved for use, however, it does not
More informationWhile there is around a 3% increase shown in costs for Category M lines, I think this is due to the inclusion of more lines in Category M.
April 2018 The usual quarterly of Category M prices Another set of similar comments as I made in January: significant increases in many lines which have been subject to price concessions but even more
More informationUse of Psychotropic Medications in Older Adults with Dementia!
Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with
More informationDT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 702 M %
December 16 No Category M changes so the reductions imposed in May which were only supposed to last until September continue As in November, most changes are Category A lines with a few Category C. Significant
More informationChapter 4 Central Nervous System Answers. 1. What advice would you provide to someone who has just been initiated on Temazepam for insomnia?
Chapter 4 Central Nervous System Answers 1. What advice would you provide to someone who has just been initiated on Temazepam for insomnia? May impair judgement and increase reaction time, and so affect
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationPerinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs
Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service
More informationDerbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY
Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY Chapter 4: CENTRAL NERVOUS SYSTEM Updated: March 2017 Drugs and driving From March 2015 a new driving offence
More informationS H A R E D P R E S C R I B I N G G U I D E L I N E
S H A R E D P R E S C R I B I N G G U I D E L I N E Introduction This shared prescribing guideline for the second generation antipsychotic medications listed above has been developed with due consideration
More informationPrescriber s Guide. Stahl s Essential Psychopharmacology
Stahl s Essential Psychopharmacology Prescriber s Guide FIFTH EDITION With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present this
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationMedicine Related Falls Risk Assessment Tool (MRFRAT)
Medicine Related Falls Risk Assessment Tool (MRFRAT) The Medicine Related Falls Risk Assessment tool (MRFRAT) in Appendix 1 is designed to help identify patients at risk of falls due to their current medicine
More informationThe Maudsley Prescribing Guidelines in
The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief
More informationMethylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement
Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationGuidelines on Choice and Selection of Antidepressants for the Management of Depression
Guidelines on Choice and Selection of Antidepressants for the Management of Depression 1. Introduction This guidance should be considered as part of a stepped care approach in the management of depressive
More informationPsychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson
Psychotropic Drug Therapy in Adults with Learning Disability Steve Wilkinson Outline and Aims of the Session Drug use in learning disability Two distinct areas of drug therapy I. Treatment of common psychiatric
More informationDrugs used for the treatment of depression Selective Serotonin Reuptake Inhibitors Tricyclic and related antidepressants Others antidepressants
Central Nervous System Drugs used for the treatment of depression Anxiolytics and hypnotics Drugs used in psychosis and related disorders Drugs used in substance dependence for patients with established
More informationJuly Formulary Policy
Formulary Policy July 2017 Responsible Committee: Quality Committee Date Effective: July 2017 Author: Rahinatu Amadu Supersedes: July 2016 Next Review Due: July 2018 Formulary Policy 2016-2018 1. INTRODUCTION
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also
More informationGuidelines on Choice and Selection of Antidepressants for the Management of Depression
Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice
More informationFORMULARY AND PRESCRIBING GUIDANCE
FORMULARY AND PRESCRIBING GUIDANCE GUIDELINE VERSION 20 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED April 2018 NEXT REVIEW DATE (see specific guidelines) FORMULARY SPONSOR Chief Medical
More informationVolume 4; Number 5 May 2010
Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated
More informationGuidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).
Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Guidelines for the
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationMedicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay
Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay (Revised edition November 2015) The Medicine Related Falls Risk Assessment
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Step 3: GAD with marked functional impairment or that has not improved after step 2 interventionsentions bring together everything NICE says on a topic in an interactive flowchart. are interactive and
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationCalgary Long Term Care Formulary. Pharmacy & Therapeutics. February 2015
Calgary Long Term Care Formulary Pharmacy & Therapeutics February 2015 Highlights http://www.albertahealthservices.ca/4070.aspx 1 Contents February 2016... 3 Added Product(s)... 3 Not Listed, Delisted
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services DRIVING AND MENTAL HEALTH CONDITIONS AND TREATMENTS General information Driving while impaired by a physical
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationTreating sleep disorders
Treating sleep disorders Sue Wilson Centre for Neuropsychopharmacology Imperial College London sue.wilson@imperial.ac.uk Suggested algorithm for treatment of insomnia Diagnosis of insomnia Associated with
More informationEffective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine
Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This
More informationThe Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability
The Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability Danielle Adams Principal Clinical Pharmacist Pharmacy and Medicines Optimisation Team HPFT July 2017 1
More informationPRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist
PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines
More informationSupply should only occur if requesting signature is on approved list held by the issuing pharmacy
Trust Approved Drugs List March 2016 The following is the list of drugs that are approved by the EEAST Medicines Management Group for use by EEAST clinical staff. Pharmacies are advised that this is the
More informationDT Description Price Category Price change Percentage
June 2017 A slight inflationary pressure in most CCGs from mainly Category A increases. Significant price increases: Most of low concern although those involving the less frequently used tamoxifen strengths
More informationAnswer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.
CLINICAL THERAPEUTICS 7: PSYCHIATRY PHA-MHBY Time allowed: 2 hours UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-2014 Part ONE Answer ALL questions. For each question, there
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationGuidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act
Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act This guidance is intended for Coventry and Warwickshire Partnership Trust staff to use when
More informationPrimary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia
Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationGUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)
GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) Introduction Aripiprazole long-acting injection (LAI)is licensed for the maintenance treatment of adult patients with schizophrenia
More informationTobacco Dependence Treatment Pathway
Tobacco Dependence Treatment Pathway GUIDELINE VERSION 1 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED January 2017 NEXT REVIEW DATE January 2019 FORMULARY SPONSOR Executive Medical
More informationPaliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)
Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) 1. Key Points 1.1 Paliperidone palmitate 3-monthly long-acting
More informationClinical. Off-label and Unlicensed Medicines Policy. Document Control Summary. Contents
Clinical Off-label and Unlicensed Medicines Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date:
More informationMedicines used in Mental Health
Publication Report Medicines used in Mental Health Years 24/5 to 214/15 Publication date 13 October 215 A National Statistics Publication for Scotland Contents Introduction... 2 Hypnotics & Anxiolytics...
More informationPharma X Consultancy Inc. Inventory List
Pharma X Consultancy Inc. Inventory List Location: Pharma X Consultancy Inc 2 Aceclofenac 100mg Tablets 60S 1205 ID Aciclovir 200mg Tablets 25S 1213 Aciclovir 400mg Tablets 56S 1214 Aciclovir 5% Cream
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationPalliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers
Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers This formulary is current as of February 11, 2010. Important Notes: Pharmacists must submit a claim on PharmaNet at the time
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationSMOKING AND DRUG INTERACTIONS
Medicines Information Centre Pharmacy Department UK Medicines Information SMOKING AND DRUG INTERACTIONS Introduction Smoking rates are significantly higher among people with mental health problems. It
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationBirmingham and Solihull Mental Health NHS Foundation Trust. Formulary. March 2013
Birmingham and Solihull Mental Health NHS Foundation Trust Formulary March 2013 1 Table of contents Antipsychotics Introduction p3 1. Antipsychotics available p4 2. Mood stabilisers available p5 3. Prescribing
More informationClinical. Off-label and Unlicensed Medicines Policy. Document Control Summary. Contents
Clinical Off-label and Unlicensed Medicines Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date:
More information